Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)

Riya R Parikh; Khushbu R Patel; Joseph V Pergolizzi Jr; Frank Breve; Peter Magnusson

doi:10.7759/cureus.22778

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)

Cureus. 2022 Mar 2;14(3):e22778. doi: 10.7759/cureus.22778. eCollection 2022 Mar.

Authors

Riya R Parikh¹, Khushbu R Patel¹, Joseph V Pergolizzi Jr², Frank Breve¹, Peter Magnusson^{3

4}

Affiliations

¹ Department of Pharmacy, Temple University, Philadelphia, USA.
² Cardiology, Native Cardio Inc., Naples, USA.
³ Cardiology, School of Medical Sciences, Örebro University, Örebro, SWE.
⁴ Medicine, Cardiology Research Unit, Karolinska Institutet, Stockholm, SWE.

Abstract

In this review, we evaluated the literature on the benefits and deleterious effects of digoxin in heart failure (HF) with reduced ejection fraction (EF). Although digoxin was considered an effective treatment for HF, the supporting evidence is conflicting. Before the conventional use of modern HF therapies, digoxin was widely used for symptomatic relief on these patients. Further randomized trials are required to reach a definite conclusion about its efficacy and safety in patients experiencing HF with a reduced EF (HFrEF).

Keywords: cardiovascular; cv; digitalis; digoxin; heart failure; hfref; mortality; readmission; reduced ejection fraction; rehospitalization.

Publication types

Review